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The use of ketorolac injections in Indonesia is restricted with the 
provision of 2-3 ampoules per day with a maximum of two days even though 
the literature states that ketorolac could be used for no more than five days. 
This study aimed to determine the decrease in pain scale as well as 
gastrointestinal and renal adverse effects of ketorolac injections in two days 
of use. This study was an observational study with a one-group pre-test post-
test design conducted prospectively. The group was a group of patients with 
postoperative pain who received ketorolac injections and were treated 
during January till April 2018 in an academic hospital in Yogyakarta. The 
results showed that ketorolac injections did not provide a statistically 
significant decrease in pain scale in two days of use compared to before 
surgery (median [range] = 2.0[0.0-9.33] vs 1.33[0.0-8.33]; p=0.32). Ketorolac 
injections decreased the kidney function of subjects in two days of use 
compared to before surgery based on creatinine values (0.76mg/dL vs 
0.80mg/dL; p=0.024) and GFR (96.13mL/min/m2 vs 87.52mL/min/m2; 
p=0.023), and as many as 31 subjects (43.06%) experienced complaints that 
were suspected to be the gastrointestinal adverse effects of ketorolac 
injections with the three most complaints were bloating (18.06%), nausea 
(16.67%), and heartburn (15.28%). Those three results support the use of 
ketorolac injections following what has been regulated in the Indonesian 
National Formulary. 
Keywords: Pain scale, gastrointestinal adverse effects, renal adverse effect, 
ketorolac injections, postoperative. 
 
INTRODUCTION 
Postoperative pain is an unexpected 
subjective complaint. Data on the prevalence of 
postoperative pain in Indonesia is still not well 
documented, but in other countries such as studies 
conducted in Barcelona, it had shown that the 
prevalence of orthopedic postoperative pain and 
trauma was around 28% with mild pain of 15% 
and moderate to severe pain by 13% (Robleda et 
al., 2014). Another study showed that moderate to 
severe pain in the first 24h and the first 48h after 
surgery were 13% and 11.7%, respectively 
(Mwaka et al., 2013). Ketorolac is one of the drugs 
of choice for postoperative pain management. A 
study showed that 89.7% of patients with 
postoperative pain in one hospital in Indonesia 
were treated using ketorolac (Permata, 2014). 
The results of several other studies showed 
that ketorolac could provide better postoperative 
pain management than placebo, tramadol (Shah et 
al., 2013), diclofenac (Mony et al., 2016), and 
significantly reduced pain intensity 30 minutes 
after surgery (Eftekharian and Pak, 2017). 
However, the risk of gastrointestinal bleeding due 
to ketorolac was known to be quite high and 
relatively higher than other NSAIDs. The results of 
a study showed that nonselective NSAIDs 
increased the relative risk of bleeding, but 
ketorolac could increase the risk of bleeding much 
even higher (Gonza´lez et al., 2010). A study that 
examined the association between NSAIDs and 
chronic kidney disease (CKD) showed that 
ketorolac increased the risk of CKD by 2.54 times 
in less than 3 months (Ingrasciotta et al., 2015) and 
acute renal failure by 2.08 times if given for more 
than 5 days (Feldman et al., 1997). In addition, 
other studies that have been conducted showed 
that in addition to gastrointestinal bleeding, the 
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adverse effects that may arise in 48 hours of 
ketorolac injections use in postoperative patients 
were; nausea/vomiting 37.5%; dizziness 25%; 
dyspepsia 8.7%; pruritus 6.2%; and constipation 
3.1% (Siribumrungwong et al., 2015). 
The use of ketorolac injections is generally 
restricted for no more than five days (Grosser et al., 
2018; Strom et al., 1996), but the use of ketorolac 
injections in Indonesia is restricted with the 
provision of 2-3 ampoules per day with a 
maximum of two days by the Indonesian National 
Formulary (Kementerian Kesehatan, 2016). This 
certainly raises the question whether ketorolac 
influences the decrease in pain scale adequately 
and whether gastrointestinal and renal adverse 
effects will indeed appear in just two days. 
Therefore, this study aimed to determine the 
decrease in pain scale along with gastrointestinal 
and renal adverse effects of ketorolac injections in 
two days of use.  
 
MATERIAL AND METHODS 
Study design 
This study was an observational study with 
a one-group pre-test post-test design conducted 
prospectively. This study only consisted of one 
group, namely the group of patients who received 
ketorolac injections. The study was conducted in 
the surgical ward of an academic hospital in 
Yogyakarta since January till April 2018. The 
design of this study was approved by the Research 
Ethics Committee of the Faculty of Medicine (now 
is the Faculty of Medicine, Public Health, and 
Nursing) of the Universitas Gadjah Mada with 
number KE/FK/1033/EC/2017. 
 
Population and samples of study 
The population of this study was all surgical 
patients hospitalized in the surgical ward of the 
study hospital, while the study samples were all 
patients aged ≥18 years with postoperative pain 
who received ketorolac injections during 
hospitalization in the surgical ward and were not 
included in the exclusion criteria specified in the 
study. The exclusion criteria of this study 
consisted: 1) Patients who were unconscious after 
completing surgery; 2) Patients with a history of 
peptic ulcer, chronic kidney disease, or were 
experiencing nausea, vomiting, diarrhea, and 
constipation before undergoing surgery. 
 
Data collection 
The collection of study subjects involved 
physicians who treated the patients and it was 
performed using consecutive sampling method. 
The physicians asked the patients to participate in 
the study by signing an informed consent sheet 
before undergoing surgery. After the patients 
agreed to participate as study subjects, the 
patients’ pain scale was assessed using a numeric 
rating scale (NRS) instrument (Hawker et al., 
2011) and determined as the baseline pain scale. 
The patients’ pain scale was reassessed on the first 
and second day after surgery. Complaints or 
symptoms that were thought to be ketorolac 
adverse effects were monitored during treatment. 
Suspected adverse effects were adverse effects that 
lead to gastrointestinal and renal. Identification of 
gastrointestinal adverse effects of ketorolac 
injections use was performed using the Naranjo 
adverse drug reaction probability questionnaire 
(Belhekar et al., 2014), whereas the identification 
of renal adverse effects was carried out by 
examining the patients’ serum creatinine and 
Blood Urea Nitrogen (BUN) values.  
 
Data analysis 
Numerical data were processed in decimal 
form with the central tendency of data in the form 
of mean ± SEM (Standard Error of Mean) if the data 
is normally distributed statistically, or in the form 
of median if the data were not normally distributed. 
Patient data that were categorized were processed 
in the form of proportions. Both types of data were 
then presented in the form of tables or figures. 
The analysis of decrease in pain scale was 
done by comparing the pain scale before surgery 
with the pain scale on the day one and day two 
after surgery, whereas the analysis of decrease in 
kidney function was done in two ways, namely by 
comparing creatinine values before undergoing 
surgery with creatinine values on day two after 
surgery, and by comparing values of GFR before 
undergoing surgery with GFR on day two after 
surgery. Measurement of the value of GFR was 
done using the MDRD4 formula (Levey et al., 
2000). Before analyzing the decrease in the pain 
scale and kidney function, the investigators 
conducted a data distribution normality test using 
the Shapiro-Wilk test. Then, the significance of the 
decrease in pain scale and kidney function 
(creatinine and GFR) was tested using paired t-test 
if the data were normally distributed or the 
Wilcoxon test if the data were not normally 
distributed statistically. The p-value of <0.05 
showed that the pain scale or kidney function 
before undergoing surgery were significantly 
different from day one or two after surgery. 
Mawardi Ihsan 
Volume 30 Issue 2 (2019)   135 
RESULTS AND DISCUSSION 
This study aimed to: 1) to determine the 
adequacy of the decrease in the patients’ pain scale 
given by injections of ketorolac on day one and day 
two after surgery, 2) to determine the effect of 
ketorolac injections on kidney function on day two 
after surgery, and 3) to investigate complaints 
suspected of being an adverse effect of ketorolac 
injections. This study was beneficial as a basis for 
evaluating the restrictions on the use of ketorolac 
injections according to the Indonesian National 
Formulary, which states that ketorolac injections 
are only given in a maximum of two days with a 
dose of 2-3 ampoules per day (Kementerian 
Kesehatan, 2016) even though Vadivelvu et al. 
(2017) states that ketorolac use may be used for 
not more than five days (Grosser et al., 2018; 
Vadivelu et al., 2017).  
 
Characteristics of study subjects 
The subjects of this study were surgical 
patients who were hospitalized and received 
ketorolac injections as a postoperative analgesic 
since February to April 2018 in the study site 
hospital. The types of surgery included in this 
study were general surgery, digestive surgery, and 
orthopedic surgery. 
The subject collection was carried out by a 
consecutive sampling method and this study finally 
obtained a total of 72 patients. In general, the 
characteristics of the subjects in this study were 
general surgical patients aged 46-60 years with a 
mean age of 46.76±1.90 years, female gender, not 
smoking, with comorbid of hypertension and 
received ketorolac injection dose of 30mg every 8h 
during treatment (Table I). Also, the study subjects 
admitted the hospital with a pain scale of 
2.13±0.28 and normal kidney function which was 
seen through normal BUN, creatinine, and GFR 
values. 
 
The decrease in pain scale  
This study was conducted with a one group 
pre-test post-test design so that the statistically 
Table I. Characteristics of study subjects 
 
Characteristics Mean 𝒙 ± SEM (N=72) Proportion n (%) (N=72) 
Age (years) 46.76±1.90  
Baseline blood pressure (mmHg) 124.67±1.95/77.25±0.99  
Baseline pain scale 2.13±0.28  
Baseline BUN (mg/dL) (N=43a) 25.70±1.57a  
Baseline creatinine (mg/dL) (N=43a) 0.84±0.03a  
Baseline GFR (mL/min/1.73 m2) 
(N=43a) 
95.34±3.39a  
Age groups 
 
-19-35 years 
-36-45 years 
-46-60 years 
-61-75 years 
-76-90 years 
 17 (23.6) 
15 (20.8) 
24 (33.3) 
14 (19.4) 
2 (2.8) 
Gender 
 
-Male 
-Female 
 32 (44.4) 
40 (55.6) 
Smoking status 
 
-Yes 
-No 
 13 (18.1) 
59 (81.9) 
Types of surgery 
 
-general surgery 
-digestive surgery 
-orthopedic surgery 
 32 (44.44) 
27 (37.5) 
13 (18.1) 
Comorbid 
 
-hypertension 
-diabetes 
-asthma 
-vertigo 
 11 (15.28) 
9 (12.5) 
4 (0.06) 
2 (0.03) 
Ketorolac dose 
 
-30mg every 8h 
-30mg every 12h 
 70 (97.2) 
2 (2.8) 
 
a=measured from only 43 patients who had complete BUN, creatinine, and GFR values on the day before undergoing 
surgery. 
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tested data were only the completely paired data. 
This caused the number of subjects analyzed on the 
comparison of pain scale on the day before surgery 
with the day one after surgery was not the same as 
in the analysis on the comparison of the pain scale 
on the day before surgery with the day two after 
surgery. 
Ketorolac injections did not decrease the 
pain scale on day one after surgery but were able 
to decrease the pain scale on day two after surgery 
(Figure 1). However, the decrease in the pain scale 
on day two after surgery produced by ketorolac 
injection was not significant. This indicated that 
the problem of postoperative pain was still 
unresolved using ketorolac injections as is 
presented in the pain management guidelines 
published by the American Pain Society (2016) 
which states that less than half of patients with 
postoperative pain report adequate postoperative 
pain relief (Chou et al., 2016). 
A similar study was conducted by 
Eftekharian and Pak (2017) in which the study 
investigated the effects of intravenous ketorolac on 
postoperative pain in patients with mandibular 
fractures, but the pain measured was early 
postoperative pain. One study showed that 
ketorolac did not provide a pain scale that was 
different significantly with the placebo group in the 
first 4h after surgery (pain intensity 1.08±0.49 vs 
1.04±0.68; p=0.135; scores on Visual Analog Scale 
(VAS) >1=16% compared to 24%, p=0.725) 
(Eftekharian and Pak, 2017). There is still no 
agreement of opinion in the definition of relieving 
or control of pain although O'neil (2016) states that  
one example of pain management in patients with 
acute pain is pain with a scale of less than 3 (O’Neil, 
2016). 
 
The decrease in renal function  
The study subjects included in the analysis 
of the decrease in kidney function in this study 
were subjects with complete creatinine level data 
before undergoing surgery and on day two after 
surgery so that the number of subjects analyzed 
amounted to only 23 patients. This study analyzed 
the decline in kidney function of the study subjects 
using serum creatinine and GFR parameters. 
The results showed that ketorolac injections 
caused an increase in serum creatinine levels on 
day two after surgery (Figure 2). Although the 
increase in the value was slight (0.4mg/dL), the 
results of statistical tests showed that the increase 
in the value was statistically significant. The GFR 
parameter was used to ensure that changes in 
kidney function occur because creatinine is a less 
specific parameter of kidney function. Creatinine is 
the end-product of nitrogen metabolism which is 
excreted in the urine. Creatinine production reflects 
total body muscle mass (Rae et al., 2018) so that 
the same creatinine levels among subjects could 
show different kidney function due to different 
muscle mass in different ages and genders. 
Therefore, this study used GFR which is a more 
specific kidney function parameter. The results of 
the study also showed that the decline in kidney 
function in the subjects of the study consistently 
occurred when viewed using the GFR parameter 
(Figure 3). 
  
 
 
Figure 1. Median of pain scale from the day before surgery until day two after surgery. a=not significantly 
different with a Z score of -1.02 between before the surgery and the day one after surgery (p=0.31). b=not 
significantly different from the Z score of -0.994 before the surgery and day two after surgery (p=0.32). 
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Authors found that it is difficult to find 
relatively new studies of ketorolac, but because 
ketorolac is a drug belonging to the group of 
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) 
(Candido et al., 2017) and because studies of 
NSAIDs generally included various types of NSAIDs 
including ketorolac, then a discussion of NSAID 
adverse effects on the kidneys could apply to 
ketorolac. Candido et al. (2017) mentioned that 
NSAIDs only caused a temporary mild decrease in 
kidney function on day one after surgery. The 
decrease was measured using creatinine clearance 
parameters in 1,450 healthy adults with a yield of 
16 mL/min [5-28 mL/min] which was not 
significant compared to the placebo group 
(Candido et al., 2017). A systematic review study 
conducted by Zhang et al. (2017) showed that 
patients who were exposed to NSAIDs had an 
increased risk of Acute Kidney Injury (AKI) (OR 
1.73 [1.44-2.07]) (Zhang et al., 2017).  
 
 
Figure 2. Median serum creatinine value from the day before undergoing surgery and day two after surgery. 
The study subjects included in this analysis of the increase in creatinine serum value were subjects with 
complete creatinine level data before surgery and on day two after surgery (n=23) so that it was different 
with the number of subjects in the table of study subjects’ characteristics (n=43) (Table I). Therefore, the 
serum creatinine value between this figure 2 and table I was also different. *=Statistically significant 
difference with a Z score of -2.25 of creatinine levels before undergoing surgery with day two after surgery 
(p=0.024). 
 
 
 
 
Figure 3. Mean GFR from days before undergoing surgery and day two after surgery. The number of study 
subjects included in this analysis of the decrease in GFR value (n=23) was different with the number of 
subjects in the table of study subjects’ characteristics (n=43) (Table I) because the subjects were subjects 
with complete creatinine level data before surgery and on day two after surgery. Therefore, the GFR value 
between this figure and table I was also different. *=statistically significant with a difference in the mean 
GFR of 8.61±3.51mL/min/1.73 m2 compared to the GFR value on the day before surgery (p=0.023). 
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The results of the study are supported by a 
study conducted by Chou et al. (2016) whose 
results showed that the use of NSAIDs increased 
the risk of AKI (OR 2.73 [2.28-3.28] in patients with 
current NSAID use and with OR 1.17 [1.01-1.35] in 
patients with NSAID use 30 days beforehand) (C.-I. 
Chou et al., 2016). NSAIDs do not only increase the 
risk of AKI but also End-Stage Renal Disease 
(ESRD) as in the results of a study conducted by 
Chang et al. (2015) (OR 2.72 [2.60-2.82]) (Chang et 
al., 2015). 
Two mechanisms of NSAIDs-induced AKI in 
children have been estimated. Both mechanisms 
may also apply to cases of AKI induced by NSAIDs 
in adults. The two mechanisms are the mechanism 
of hemodynamic changes and Acute Interstitial 
Nephritis (AIN). The first mechanism causes 
around 78% of AKI cases to occur, while the second 
mechanism is around 22% (Misurac et al., 2013). 
In the first mechanism, NSAIDs inhibit 
cyclooxygenase (COX) so that prostaglandin 
synthesis is inhibited. Prostaglandin acts as a 
vasodilation regulator that maintains adequate 
renal perfusion. The inhibition of prostaglandin 
synthesis causes uncontrolled vasoconstriction in 
afferent arterioles so that GFR decreases and 
causes acute ischemia and acute tubular necrosis. 
The AKI case in the second mechanism is also 
caused by NSAIDs which also inhibit COX, but the 
effect of this is the shift in arachidonic acid 
metabolism towards the pathway that synthesizes 
more leukotrienes, whereas leukotrienes are 
involved in the activation of the inflammatory 
response (Faught et al., 2015).  
 
Complaints which suspected as adverse effects 
of ketorolac injections 
The two instruments generally used to 
measure adverse effects are Naranjo and the WHO-
UMC scale (Belhekar et al., 2014), but the 
measurement of adverse effects in this study used 
a questionnaire developed by Naranjo. This 
questionnaire uses a scoring system that is divided 
into five probability categories consisting of 
definite, probable, possible and doubtful. Most of 
the complaints issued as the adverse effects of 
ketorolac injections in this study were categorized 
as probable category with a score of 5-8 (max. 13).  
The results showed that the most and least 
common adverse effects of ketorolac injections 
were bloating (18.06%) and constipation (1.29%) 
(Figure 4). The overall incidence of complaints 
suspected of being an adverse effect of ketorolac 
injections was high because complaints occurred 
in almost half of the study subjects (43.06%). The 
results of this study were slightly different from the 
results of a study conducted by Siribumrungwong 
et al. (2015) which, in that study the most common 
ketorolac adverse effects were nausea/vomiting 
(37.5%), while the least was constipation (3.1%) 
(Siribumrungwong et al., 2015). However, in this 
study, nausea was the second most common 
complaint suspected as an adverse effect of 
ketorolac injections with a proportion of 16.67%. 
 
 
 
Figure 4. Events and proportions of each adverse effect suspected caused by ketorolac injections. 
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Another important adverse effect to note was that 
ketorolac could increase the risk of gastrointestinal 
bleeding the highest compared to other NSAIDs 
(OR 14.54 [5.87-36.04]) (Gonza´lez et al., 2010) 
based on adverse effect conducted by Gonzalez et 
al. (2010).  
This study certainly had limitations. This 
study was an observational study that did not 
provide intervention to study subjects such as 
temporary stopping the ketorolac injections and 
re-challenging it after being stopped so that the 
measurement of the adverse effects of ketorolac 
injections in this study did not produce adverse 
effects that could reach definite degree. Complaints 
with probable degree still leave the possibility that 
the complaint was not due to ketorolac injections, 
but due to other factors such as patient 
comorbidities so that further studies with the 
interventional design conducted prospectively 
could improve the results of this study. 
 
CONCLUSION 
The conclusion that could be drawn from 
the results and discussion of this study is that two 
days of ketorolac injections use was not able to 
significantly decrease the postoperative pain scale 
statistically. Also, gastrointestinal adverse effects 
occurred with the two most common forms of 
bloating and nausea. The study also showed that 
the use of ketorolac injections for two days 
decreased kidney function as seen from an 
increase in serum creatinine levels and a decrease 
in GFR in the study subjects. Those three things can 
be the basis for consideration of the use of 
ketorolac injections for only two days following as 
regulated in the Indonesian National Formulary. 
 
ACKNOWLEDGMENT 
The authors say thank you to Agung 
Widianto, Adam Moeljono, and Wahyu Kartiko 
Tomo as the physicians who helped investigators 
to collect the study subjects. The authors also say 
thank you to Partini and the other nurses who 
practiced on the surgical ward of study site who 
had helped in taking blood samples from the study 
subjects. 
 
REFERENCES 
Belhekar MN., Taur SR. and Munshi RP., 2014. A 
study of agreement between the Naranjo 
algorithm and WHO-UMC criteria for 
causality assessment of adverse drug 
reactions. Indian J. Pharmacol. 46, 117. 
Candido K.., Perozo OJ. and Knezevic NN., 2017. 
Pharmacology of Acetaminophen, 
Nonsteroidal Antiinflammatory Drugs, and 
Steroid Medications: Implications for 
Anesthesia or Unique Associated Risks. 
Anesthesiol. Clin. 35, e145–e162. 
Chang Y-K., Liu J-S., Hsu Y-H., Tarng D-C., and Hsu 
C-C., 2015. Increased Risk of End-Stage 
Renal Disease (ESRD) Requiring Chronic 
Dialysis is Associated With Use of 
Nonsteroidal. Medicine (Baltimore). 94, 1–7. 
Chou C-I., Shih C-J., Chen Y-T., Ou S-M., Yang C-Y., 
Kuo S-C. and Chu D., 2016. Adverse Effects of 
Oral Nonselective and cyclooxygenase- 2-
Selective NSAIDs on Hospitalization for 
Acute Kidney Injury. Medicine (Baltimore). 
95, 1–5. 
Chou R., Gordon DB., Leon-Casasola OA. de 
Rosenberg JM. and Bickler S., et al., 2016. 
Management of postoperative pain: A 
clinical practice guideline from the 
American pain society, the American society 
of regional anesthesia and pain medicine, 
and the American society of 
anesthesiologists’ committee on regional 
anesthesia, executive commi. J. Pain 17, 
131–157. 
Eftekharian HR., and Pak HI., 2017. Effect of 
Intravenous Ketorolac on Postoperative 
Pain in Mandibular Fracture Surgery; A 
Randomized, Double-Blind, Placebo-
Controlled Trial. Bull. Emerg. Trauma 5, 13–
17. 
Faught LN., Greff MJE., Rieder MJ. and Koren G., 
2015. Drug-induced acute kidney injury in 
children. Br. J. Clin. Pharmacol. 80, 901–909. 
Feldman HI., Kinman JL., Berlin JA., Hennessy S., 
Kimmel SE., Farrar J., Carson JL. and Strom 
BL., 1997. Parenteral Ketorolac: The Risk for 
Acute Renal Failure. Ann. Intern. Med. 126, 
193–199. 
Gonza´lez ELM., Patrignani P., Tacconelli S., and 
Rodrı´guez LAG., 2010. Variability Among 
Nonsteroidal Antiinflammatory Drugs in 
Risk of Upper Gastrointestinal Bleeding. 
Arthritis Rheum. 62, 1592–1601. 
Grosser T., Smyth EM. and FitzGerald GA., 2018. 
Pharmacotherapy of Inflammation, Fever, 
Pain, and. In: Brunton, L.L., Hilal-Dandan, R., 
Knollmann, B.C. (Eds.), The Goodman & 
Gilman’S The Pharmacological Basis of 
Therapeutics. McGraw Hill, New York, pp. 
687–709. 
Hawker GA., Mian S., Kendzerska T. and French M., 
2011. Measures of adult pain: Visual Analog 
An Observational Study in Patients with Postoperative Pain 
140   Volume 30 Issue 2 (2019) 
Scale for Pain (VAS Pain), Numeric Rating 
Scale for Pain (NRS Pain), McGill Pain 
Questionnaire (MPQ), Short-Form McGill 
Pain Questionnaire (SF-MPQ), Chronic Pain 
Grade Scale (CPGS), Short Form-36 Bodily 
Pain Scale (SF. Arthritis Care Res. 
(Hoboken)). 63, S240–S252. 
Ingrasciotta Y., Sultana J., Giorgianni F., Fontana A., 
Santangelo A. et al., 2015. Association of 
Individual Non-Steroidal Anti- 
Inflammatory Drugs and Chronic Kidney 
Disease: A Population-Based Case Control 
Study. PLoS One 10, e0122899. 
Kementerian Kesehatan, 2016. Keputusan Menteri 
Kesehatan Republik Indonesia Nomor 
HK.02.02/Menkes/137/2016 Tentang 
Perubahan Atas Keputusan Menteri 
Kesehatan Nomor 
HK.02.02/Menkes/523/2015 Tentang 
Formularium Nasional. Kementrian 
Kesehatan Republik Indonesia, Indonesia. 
Levey A., Greene T., Kusek J., and Beck G., 2000. A 
simplified equation to predict glomerular 
filtration rate from serum creatinine. J. Am. 
Soc. Nephrol. 11, 155A. 
Misurac JM., Knoderer CA., Leiser JD., Nailescu C., 
Wilson AC. and Andreoli SP., 2013. 
Nonsteroidal anti-inflammatory drugs are 
an important cause of acute kidney injury in 
children. J. Pediatr. 162, 1153–1159. 
Mony D., Kulkarni D. and Shetty L., 2016. 
Comparative Evaluation of Preemptive 
Analgesic Effect of Injected Intramuscular 
Diclofenac and Ketorolac After Third Molar 
Surgery-A Randomized Controlled Trial. J. 
Clin. Diagnostic Res. 10, ZC102–ZC106. 
Mwaka G., Thikra S., and Mung’ayi V., 2013. The 
Prevalence of Postoperative Pain in The 
First 48 Hours Following Day Surgery at a 
Tertiary Hospital in Nairobi. Afr. Health Sci. 
13, 768–776. 
O’Neil CK., 2016. Pain Management. In: Chisholm-
Burns, M.A., Schwinghammer, T.L., Wells, 
B.G., Malone, P.M., Kolesar, J.M., DiPiro, J.T. 
(Eds.), Pharmacotherapy: Principles and 
Practice. McGraw Hill, pp. 521–533. 
Permata VA., 2014. Penggunaan Analgesik Pasca 
Operasi Orthopedi di RSUP dr. Kariadi 
Semarang. Universitas Diponegoro. 
Rae P., Crane M. and Pattenden R., 2018. Clinical 
Biochemistry: Lecture Notes, 10th ed. 
Wiley-Blackwell. 
Robleda G., Sillero-Sillero A., Puig T., Gich I. and 
Baños J-E., 2014. Influence of Preoperative 
Emotional State on Postoperative Pain 
Following Orthopedic and Trauma Surgery. 
Rev. Lat. Am. Enfermagem 22, 785–791. 
Shah AV., Kumar KVA., Rai KK. and Kumar BPR., 
2013. Comparative Evaluation of Pre-
Emptive Analgesic Efficacy of Intramuscular 
Ketorolac Versus Tramadol Following Third 
Molar Surgery. J. Maxillofac. Oral Surg. 12, 
197–202. 
Siribumrungwong K., Cheewakidakarn J., 
Tangtrakulwanich B., and Nimmaanrat S., 
2015. Comparing Parecoxib and Ketorolac 
as Preemptive Analgesia in Patients 
Undergoing Posterior Lumbar Spinal 
Fusion: A Prospective Randomized Double-
Blinded Placebo-Controlled Trial. BMC 
Musculoskelet. Disord. 16, 1–8. 
Strom BL., Berlin JA., Kinman JL., Spitz PW., 
Hennessy S., Feldman H., Kimmel S. and 
Carson JL. 1996. Parenteral ketorolac and 
risk of gastrointestinal and operative site 
bleeding: A postmarketing surveillance 
study. J. Am. Med. Assoc. 275, 376–382. 
Vadivelu N., Chang D., Helander EM., Bordelon GJ., 
Kai A. et al., 2017. Ketorolac, Oxymorphone, 
Tapentadol, and Tramadol: A 
Comprehensive Review. Anesthesiol. Clin. 
35, e1–e20. 
Zhang X., Donnan PT., Bell S. and Guthrie B., 2017. 
Non-steroidal anti-inflammatory drug 
induced acute kidney injury in the 
community dwelling general population and 
people with chronic kidney disease: 
systematic review and meta-analysis. BMC 
Nephrol. 18, 1–12. 
 
 
